/
Oncology
Castration-Resistant Prostate Carcinoma
18
Pipeline Programs↗
11
Active Trials↗
13
Companies Involved↗
Castration-Resistant Prostate Carcinoma is an emerging landscape with 18 programs across 13 companies. The most active players are Daiichi Sankyo.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 214
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
15 of 19 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
Trial Status
13
clinical trials
Recruiting6 · 46%
Active, not recruiting5 · 38%
Suspended1 · 8%
Terminated1 · 8%
Clinical Trials
Trial Activity
13 trials
Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy
Recruiting·—·Preclinical·NCT05113537·30 enrolled
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Active, not recruiting·—·Phase 2·NCT04471974·61 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)